|[April 23, 2014]
Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(Business Wire)--
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced the pricing
of its underwritten public offering of 2,000,000 shares of its common
stock at a public offering price of $44.00 per share, before
underwriting discounts. All of the shares in the offering are to be sold
by Agios. In addition, Agios has granted the underwriters a 30-day
option to purchase up to an additional 300,000 shares of common stock at
the public offering price, less the underwriting discount.
The offering is expected to close on or about April 29, 2014, subject to
customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint
book-running managers for the offering. Cowen and Company, LLC and
Leerink Partners LLC are serving as co-managers.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on April 23, 2014.
The offering is being made only by means of a prospectus, copies of
which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus
Department, 200 West Street, New York, NY 10282, telephone:
866-471-2526, facsimile: 212-902-9316, e-mail: firstname.lastname@example.org.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and inborn errors of metabolism, or IEMs, which
are rare genetic metabolic diseases, through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and/or preclinical development.
[ Back To TMCnet.com's Homepage ]